drug_type
RELEVANT_DRUG
intervention_type
Biological
drug_description
Autologous tumor-infiltrating lymphocyte (TIL) adoptive cell therapy composed of ex vivo–expanded patient CD8+/CD4+ TILs reinfused to mediate TCR-dependent recognition and cytotoxic killing of tumor antigen–bearing cells.
nci_thesaurus_concept_id
C187659
nci_thesaurus_definition
A preparation of autologous tumor infiltrating lymphocytes (TILs) derived from each patients resected tumor and expanded ex vivo, with potential immunomodulating and antineoplastic activities. Upon administration back into the patient, the autologous TILs LM103 specifically recognize and kill the patients tumor cells.
drug_mesh_term
Lymphocytes, Tumor-Infiltrating
drug_category
TUMOR INFILTRATING LYMPHOCYTES
drug_class
Unedited cells
drug_delivery_route
Intravenous
drug_mechanism_of_action
Autologous, ex vivo–expanded CD8+/CD4+ tumor-infiltrating T lymphocytes are reinfused to recognize tumor antigen–bearing cells via native TCRs and mediate cytotoxic killing (e.g., perforin/granzyme), leading to antitumor immune responses; product is non–genetically engineered and activity is typically supported by lymphodepletion and IL-2.
drug_name
LM103
nct_id_drug_ref
NCT05971589